Skip to main content
. 2022 Mar 14;10(3):447. doi: 10.3390/vaccines10030447

Figure 2.

Figure 2

Comparison of serum level of anti-SARS-CoV-2 IgG at (A) 12, 30, 60 and (B) 90, 120, 150, 180 days after the 2nd dose of vaccination (BNT162b2 mRNA) in patients without or with at least one adverse reaction after each vaccine dose. The data are provided as median and interquartile range. The between-group differences were calculated by the Kruskal–Wallis test.